All In MedTech

Device Trial Radar · NCT01913977

Clinical Study to Determine the Optimal Operation Parameters During CO2 Removal With the Abylcap® System

Clinical Study to Determine the Optimal Operation Parameters During CO2 Removal With the Abylcap® System.

Last checked: Nov 19, 2026Latest source record: Dec 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

4

Actual

Start

Feb 20, 2014

Primary completion

Jun 13, 2014

Study completion Sep 12, 2014

Sponsor

Lead sponsor
University Hospital, GhentAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 1, 2013

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective study includes 5 patients with ARDS (Acute Respiratory Distress Syndrome) treated by mechanical ventilation. In case of respiratory acidosis, extracorporeal CO2 (carbon dioxide)removal might be necessary. We hereby work with the Abylcap system with the oxygenator Lilliput2 as CO2 remover (Bellco, Italy). The patients (M/V) are older than 18, not pregnant, have a BMI\<30, and no contraindication for anticoagulation therapy. Under standard conditions patients are treated with a blood flow of QB=300mL/min and a gas flow (100% 02) of QG=7L/min. Blood sampling is performed from the arterial bloodline in the patients at 0, 1h, 3h, 24h, 48h, 72h, 96h, and 120h. A parameter study is also performed to optimise CO2 removal. Herewith, blood samples (1mL) are taken from the inlet and outlet line of the Lilliput2 at the previously mentioned time points and for different flow setting: Blood flow (QB) 200-300-400mL/min and gas flow (QG) 1.5, 3, 6, 7, 8L/min Blood samples are analysed for the different blood gases from which the extraction in the CO2 remover can be calculated for each setting of QB (blood flow) and QG (gas flow).

Conditions

  • ARDS (Acute Respiratory Distress Syndrome)
  • Respiratory Acidosis

Interventions

  • Abylcap® System: blood flow (QB): 200mL/min; gas flow (QG):7L/minDevice

    Abylcap settings

  • Abylcap® System: blood flow (QB): 300mL/min; gas flow (QG):7L/minDevice

    Abylcap settings

  • Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):7L/minDevice

    Abylcap settings

  • Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):1.5L/minDevice

    Abylcap settings

  • Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):3L/minDevice

    Abylcap settings

  • Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):6L/minDevice

    Abylcap settings

  • Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):8L/minDevice

    Abylcap settings

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. calculation of CO2 extraction in blood samples during mechanical ventilationTime frame: during mechanical ventilation with CO2 removal (max up to 120h)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ghent University Hospital

    Ghent, Oost-Vlaanderen, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.